Text Size

Liver Regeneration After Liver Resection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Nottingham University Hospitals NHS Trust.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Nottingham University Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT01220986
First received: October 13, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
  Purpose

The aim of this study is to characterize Kupffer cell activity and activation of the innate immune response in the early phase of liver regeneration after right hepatectomy. The investigators hypothesise that liver regeneration after right hepatectomy in humans is associated with Kupffer cell activation and initiation of the innate immune response and that impaired liver regeneration, liver failure and sepsis following liver resection are associated with Kupffer cell dysfunction and an impaired innate immune response. The objectives for this study are to characterise Kupffer cell activity and the innate immune response in human liver before and after right hepatectomy.


Condition Intervention
Liver Diseases
Hepatectomy
 Procedure: Liver biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Study of Liver Regeneration After Right Hepatectomy: Understanding the Molecular Primers of Liver Regeneration

Resource links provided by NLM:

MedlinePlus related topics: Liver Diseases
U.S. FDA Resources

Further study details as provided by Nottingham University Hospitals NHS Trust:

Biospecimen Retention:   Samples With DNA

Liver tissue & serum


Estimated Enrollment: 20
Study Start Date: August 2010
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Right hepatectomy
Intervals from inflow division.
 Procedure: Liver biopsy
0, 30, 60, 90 min post inflow-division

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing right hepatectomy for colorectal liver metastases.

Criteria

Inclusion Criteria:

  • Patients requiring right hepatectomy for colorectal liver metastases

Exclusion Criteria:

  • Age >75, neoadjuvant chemotherapy, recurrent disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01220986

Contacts
Contact: John S Hammond, BM.BS PhD 01159249924 ext 70607 john.hammond@nottingham.ac.uk

Locations
United Kingdom
Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus Recruiting
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
Sponsors and Collaborators
Nottingham University Hospitals NHS Trust
Investigators
Study Chair: Dileep N. Lobo, DM FRCS Reader in Surgery
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: John S. Hammond, Division of Surgery, NIHR Nottingham Digestive Diseases Centre BRU
ClinicalTrials.gov Identifier: NCT01220986     History of Changes
Other Study ID Numbers: NDDC10/H0403/32
Study First Received: October 13, 2010
Last Updated: October 13, 2010
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Nottingham University Hospitals NHS Trust:
Liver regeneration
Innate immune response

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on May 19, 2013